We are delighted to extend a warm welcome to Diamyd Medical as the newest corporate member of the Swedish-American Chambers of Commerce New England. Diamyd Medical’s pioneering work in precision medicine and innovative therapies for autoimmune diabetes exemplifies the kind of bold, forward-thinking vision that drives meaningful progress. Their commitment to transforming the future of Type 1 Diabetes care aligns closely with SACC-NE’s mission to champion innovation, strengthen transatlantic collaboration, and promote sustainable growth within the Swedish-American business community.

As a member of SACC-NE, Diamyd Medical gains access to a dynamic network of resources, connections, and events that will support their continued engagement and expansion in the New England region. We are excited to embark on this journey together and look forward to the positive impact Diamyd Medical will undoubtedly make within our community.

We interviewed Ulf Hannelius, President and CEO at Diamyd Medical to find out more about Diamyd Medical and what they look forward to with their new membership.

introduce your company

Diamyd Medical is a Swedish biotech company developing Diamyd®, a precision medicine for Type 1 Diabetes. It aims to help newly diagnosed patients with the HLA DR3-DQ2 genotype keep producing insulin. Diamyd® is now in Phase 3 trials in Europe and the U.S. and has received FDA Fast Track status for both treatment and prevention of Type 1 Diabetes.

Company Culture

We’re a team driven by a shared purpose—making a real difference for people with autoimmune diabetes. Our culture is collaborative and innovative, with a team of dedicated experts who work closely with a global network of clinics, researchers, and production partners. Everyone’s voice matters, and we value openness and a strong sense of commitment.

Best part of working at Diamyd Medical

Employees at Diamyd Medical get to be part of something meaningful, that has the potential to transform the treatment landscape for Type 1 Diabetes. The collaborative environment and the opportunity to contribute to cutting-edge clinical research make it a rewarding place to work. Whether you’re in research or production, you know your knowledge makes a big difference helping move a potential breakthrough therapy forward.

Diamyd Medical in 5 years

In five years, we hope Diamyd® is approved and available to patients, marking a significant advancement in the treatment of Type 1 Diabetes. We also plan to expand our therapeutic platform and our manufacturing capabilities, including achieving GMP certification for our production facility in Sweden (Umeå), to support commercialization efforts.

Why join SACC-NE?

We joined the Swedish-American Chamber of Commerce New England (SACC-NE) to connect with life science professionals and to facilitate our expansion into the U.S. market. It’s a great way to share knowledge and build relationships as we navigate the U.S. healthcare landscape.

Exciting Milestones

We recently got Fast Track status from the FDA for using Diamyd® to prevent Type 1 Diabetes in children at risk—an important step forward. We have also aligned with the U.S. FDA regarding an accelerated approval pathway for Diamyd® and raised over SEK 260 million to support our ongoing Phase 3 clinical trial and production plans.